Left Ventricular Hypertrophy: Evaluation With Cardiac MRI

Bluemke, 2008, The relationship of left ventricular mass and geometry to incident cardiovascular events: The MESA (Multi-Ethnic Study of Atherosclerosis) study, J Am Coll Cardiol, 52, 2148, 10.1016/j.jacc.2008.09.014 Kramer, 2013, Society for Cardiovascular Magnetic Resonance Board of Trustees Task Force on Standardized P. Standardized cardiovascular magnetic resonance (CMR) protocols 2013 update, J Cardiovasc Magn Reson, 15, 91, 10.1186/1532-429X-15-91 Maceira, 2006, Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance, J Cardiovasc Magn Reson, 8, 417, 10.1080/10976640600572889 Bai, 2018, Automated cardiovascular magnetic resonance image analysis with fully convolutional networks, J Cardiovasc Magn reson, 20, 65, 10.1186/s12968-018-0471-x Kawel, 2012, Normal left ventricular myocardial thickness for middle-aged and older subjects with steady-state free precession cardiac magnetic resonance: The multi-ethnic study of atherosclerosis, Circ Cardiovasc Imaging, 5, 500, 10.1161/CIRCIMAGING.112.973560 Garg, 2015, Association of a 4-Tiered classification of LV hypertrophy with adverse CV outcomes in the general population, JACC Cardiovasc Imaging, 8, 1034, 10.1016/j.jcmg.2015.06.007 Hamlin, 2014, Mapping the future of cardiac MR imaging: Case-based review of T1 and T2 mapping techniques, Radiographics, 34, 1594, 10.1148/rg.346140030 Semsarian, 2015, New perspectives on the prevalence of hypertrophic cardiomyopathy, J Am Coll Cardiol, 65, 1249, 10.1016/j.jacc.2015.01.019 Elliott, 2014, 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC), Eur Heart J, 35, 2733, 10.1093/eurheartj/ehu284 Maron, 2009, Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance, J Am Coll Cardiol, 54, 220, 10.1016/j.jacc.2009.05.006 Rickers, 2005, Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy, Circulation, 112, 855, 10.1161/CIRCULATIONAHA.104.507723 Moon, 2004, Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography, Heart, 90, 645, 10.1136/hrt.2003.014969 Maron, 2007, Right ventricular involvement in hypertrophic cardiomyopathy, Am J Cardiol, 100, 1293, 10.1016/j.amjcard.2007.05.061 Maron, 2011, Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy, Circulation, 124, 40, 10.1161/CIRCULATIONAHA.110.985812 Harrigan, 2008, Significance of papillary muscle abnormalities identified by cardiovascular magnetic resonance in hypertrophic cardiomyopathy, Am J Cardiol, 101, 668, 10.1016/j.amjcard.2007.10.032 Patel, 2015, Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy patients without severe septal Hypertrophy: Implications of mitral valve and papillary muscle abnormalities assessed using cardiac magnetic resonance and echocardiography, Circ Cardiovasc Imaging, 8, 10.1161/CIRCIMAGING.115.003132 Maron, 2012, Prevalence and clinical profile of myocardial crypts in hypertrophic cardiomyopathy, Circ Cardiovasc Imaging, 5, 441, 10.1161/CIRCIMAGING.112.972760 Captur, 2014, Prediction of sarcomere mutations in subclinical hypertrophic cardiomyopathy, Circ Cardiovasc Imaging, 7, 863, 10.1161/CIRCIMAGING.114.002411 Gersh, 2011, 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, Circulation, 124, e783 Maron, 2008, Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy, Circ Heart Fail, 1, 184, 10.1161/CIRCHEARTFAILURE.108.768119 Bruder, 2010, Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy, J Am Coll Cardiol, 56, 875, 10.1016/j.jacc.2010.05.007 O'Hanlon, 2010, Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy, J Am Coll Cardiol, 56, 867, 10.1016/j.jacc.2010.05.010 Rubinshtein, 2010, Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy, Circ Heart Fail, 3, 51, 10.1161/CIRCHEARTFAILURE.109.854026 Green, 2012, Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy, JACC Cardiovasc Imaging, 5, 370, 10.1016/j.jcmg.2011.11.021 Chan, 2014, Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy, Circulation, 130, 484, 10.1161/CIRCULATIONAHA.113.007094 Mentias, 2018, Late gadolinium enhancement in patients with hypertrophic cardiomyopathy and preserved systolic function, J Am Coll Cardiol, 72, 857, 10.1016/j.jacc.2018.05.060 Harris, 2006, Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy, Circulation, 114, 216, 10.1161/CIRCULATIONAHA.105.583500 Maron, 2008, Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy, Circulation, 118, 1541, 10.1161/CIRCULATIONAHA.108.781401 Maron, 2010, Management implications of massive left ventricular hypertrophy in hypertrophic cardiomyopathy significantly underestimated by echocardiography but identified by cardiovascular magnetic resonance, Am J Cardiol, 105, 1842, 10.1016/j.amjcard.2010.01.367 Olivotto, 2008, Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy, J Am Coll Cardiol, 52, 559, 10.1016/j.jacc.2008.04.047 Levy, 1988, Echocardiographically detected left ventricular hypertrophy: Prevalence and risk factors. The Framingham Heart Study, Ann Intern Med, 108, 7, 10.7326/0003-4819-108-1-7 Drazner, 2005, Left ventricular hypertrophy is more prevalent in blacks than whites in the general population: The Dallas Heart Study, Hypertension, 46, 124, 10.1161/01.HYP.0000169972.96201.8e Devereux, 2004, Prognostic significance of left ventricular mass change during treatment of hypertension, JAMA, 292, 2350, 10.1001/jama.292.19.2350 Peterson, 2013, Relationship of left ventricular hypertrophy and diastolic function with cardiovascular and renal outcomes in African Americans with hypertensive chronic kidney disease, Hypertension, 62, 518, 10.1161/HYPERTENSIONAHA.111.00904 Rudolph, 2009, Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy relation to remodeling, J Am Coll Cardiol, 53, 284, 10.1016/j.jacc.2008.08.064 Zywica, 2008, Dynamic left ventricular outflow tract obstruction evoked by exercise echocardiography: Prevalence and predictive factors in a prospective study, Eur J Echocardiogr, 9, 665, 10.1093/ejechocard/jen070 Hinojar, 2015, T1 mapping in discrimination of hypertrophic phenotypes: Hypertensive heart disease and hypertrophic cardiomyopathy: Findings from the International T1 Multicenter Cardiovascular Magnetic Resonance Study, Circ Cardiovasc Imaging, 8, 10.1161/CIRCIMAGING.115.003285 Galderisi, 2015, The multi-modality cardiac imaging approach to the Athlete's heart: An expert consensus of the European Association of Cardiovascular Imaging, Eur Heart J Cardiovasc Imaging, 16, 353, 10.1093/ehjci/jeu323 Pelliccia, 1991, The upper limit of physiologic cardiac hypertrophy in highly trained elite athletes, N Engl J Med, 324, 295, 10.1056/NEJM199101313240504 Caselli, 2014, Differentiating left ventricular hypertrophy in athletes from that in patients with hypertrophic cardiomyopathy, Am J Cardiol, 114, 1383, 10.1016/j.amjcard.2014.07.070 Scharhag, 2002, Athlete's heart: Right and left ventricular mass and function in male endurance athletes and untrained individuals determined by magnetic resonance imaging, J Am Coll Cardiol, 40, 1856, 10.1016/S0735-1097(02)02478-6 Maron, 1993, Reduction in left ventricular wall thickness after deconditioning in highly trained Olympic athletes, Br Heart J, 69, 125, 10.1136/hrt.69.2.125 Dweck, 2012, Left ventricular remodeling and hypertrophy in patients with aortic stenosis: Insights from cardiovascular magnetic resonance, J Cardiovasc Magn Reson, 14, 50, 10.1186/1532-429X-14-50 Barone-Rochette, 2014, Prognostic significance of LGE by CMR in aortic stenosis patients undergoing valve replacement, J Am Coll Cardiol, 64, 144, 10.1016/j.jacc.2014.02.612 Falk, 2014, How to image cardiac amyloidosis, Circ Cardiovasc Imaging, 7, 552, 10.1161/CIRCIMAGING.113.001396 Pozo, 2014, Cardiac magnetic resonance evaluation of left ventricular remodelling distribution in cardiac amyloidosis, Heart, 100, 1688, 10.1136/heartjnl-2014-305710 Maceira, 2005, Cardiovascular magnetic resonance in cardiac amyloidosis, Circulation, 111, 186, 10.1161/01.CIR.0000152819.97857.9D Syed, 2010, Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis, JACC Cardiovasc Imaging, 3, 155, 10.1016/j.jcmg.2009.09.023 Vogelsberg, 2008, Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: Noninvasive imaging compared to endomyocardial biopsy, J Am Coll Cardiol, 51, 1022, 10.1016/j.jacc.2007.10.049 White, 2014, CMR imaging with rapid visual T1 assessment predicts mortality in patients suspected of cardiac amyloidosis, JACC Cardiovasc Imaging, 7, 143, 10.1016/j.jcmg.2013.09.019 Karamitsos, 2013, Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis, JACC Cardiovasc Imaging, 6, 488, 10.1016/j.jcmg.2012.11.013 Fontana, 2014, Native T1 mapping in transthyretin amyloidosis, JACC Cardiovasc Imaging, 7, 157, 10.1016/j.jcmg.2013.10.008 Dungu, 2014, CMR-based differentiation of AL and ATTR cardiac amyloidosis, JACC Cardiovasc Imaging, 7, 133, 10.1016/j.jcmg.2013.08.015 Fontana, 2015, Differential myocyte responses in patients with cardiac transthyretin amyloidosis and light-chain amyloidosis: A Cardiac MR Imaging Study, Radiology, 277, 388, 10.1148/radiol.2015141744 Bokhari, 2013, (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses, Circ Cardiovasc Imaging, 6, 195, 10.1161/CIRCIMAGING.112.000132 Minutoli, 2013, Comparison between (99m)Tc-diphosphonate imaging and MRI with late gadolinium enhancement in evaluating cardiac involvement in patients with transthyretin familial amyloid polyneuropathy, AJR Am J Roentgenol, 200, W256, 10.2214/AJR.12.8737 Gillmore, 2016, Nonbiopsy diagnosis of cardiac transthyretin amyloidosis, Circulation, 133, 2404, 10.1161/CIRCULATIONAHA.116.021612 Patel, 2011, Cardiovascular events in patients with fabry disease natural history data from the fabry registry, J Am Coll Cardiol, 57, 1093, 10.1016/j.jacc.2010.11.018 Nakao, 1995, An atypical variant of Fabry's disease in men with left ventricular hypertrophy, N Engl J Med, 333, 288, 10.1056/NEJM199508033330504 Linhart, 2007, The heart in Anderson-Fabry disease and other lysosomal storage disorders, Heart, 93, 528, 10.1136/hrt.2005.063818 Perry, 2019, The role of cardiac imaging in the diagnosis and management of Anderson-Fabry disease, JACC Cardiovasc Imaging, 12, 1230, 10.1016/j.jcmg.2018.11.039 Sado, 2013, Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping, Circ Cardiovasc Imaging, 6, 392, 10.1161/CIRCIMAGING.112.000070 D'Souza, 2014, Danon disease: clinical features, evaluation, and management, Circ Heart Fail, 7, 843, 10.1161/CIRCHEARTFAILURE.114.001105 Dara, 2011, Danon disease: Characteristic late gadolinium enhancement pattern on cardiac magnetic resonance imaging, Cardiol Young, 21, 707, 10.1017/S1047951111000564 Seward, 2010, Infiltrative cardiovascular diseases: Cardiomyopathies that look alike, J Am Coll Cardiol, 55, 1769, 10.1016/j.jacc.2009.12.040 Poyhonen, 2015, Cardiovascular magnetic resonance findings in patients with PRKAG2 gene mutations, J Cardiovasc Magn Reson, 17, 89, 10.1186/s12968-015-0192-3 Turkbey, 2010, The impact of obesity on the left ventricle: The Multi-Ethnic Study of Atherosclerosis (MESA), JACC Cardiovasc Imaging, 3, 266, 10.1016/j.jcmg.2009.10.012 Zuccarino, 2015, Left ventricular noncompaction: Imaging findings and diagnostic criteria, AJR Am J Roentgenol, 204, W519, 10.2214/AJR.13.12326 Matsumori, 2000, Hypertrophic cardiomyopathy as a manifestation of cardiac sarcoidosis, Jpn Circ J, 64, 679, 10.1253/jcj.64.679